The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04781192
Study type	Interventional
Source	University of Kansas Medical Center
Contact	KUCC Navigation
Phone	913-588-3671
Email	kucc_navigation@kumc.edu
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	March 22, 2022
Completion date	December 2025

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05009953` - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer	Phase 2
	Recruiting	`NCT05820906` - Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer	Phase 2
	Completed	`NCT03358849` - Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer	Phase 1
	Recruiting	`NCT05410197` - Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)	Phase 2
	Active, not recruiting	`NCT04727996` - Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer	Phase 2
	Recruiting	`NCT05823987` - Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)	Phase 2
	Not yet recruiting	`NCT04733521` - A Phase 1/2 Study of SC-43 in Combination With Cisplatin	Phase 1/Phase 2
	Recruiting	`NCT04027764` - Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer	Phase 2
	Recruiting	`NCT05781074` - Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）	Phase 2
	Recruiting	`NCT05653180` - IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer	Phase 1/Phase 2
	Recruiting	`NCT04005339` - NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer	Phase 2
	Completed	`NCT04217954` - HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC	Phase 2
	Recruiting	`NCT05170438` - Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment	Phase 2
	Active, not recruiting	`NCT04172402` - NGS as the First-line Treatment in Advanced Biliary Tract Cancer	Phase 2
	Withdrawn	`NCT02597465` - A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507	Phase 3
	Active, not recruiting	`NCT04969887` - Combination Immunotherapy in Rare Cancers Under InvesTigation	Phase 2
	Recruiting	`NCT04211168` - Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers	Phase 2
	Recruiting	`NCT05812430` - Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer	Phase 2